Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00452543CT.gov Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alcohol Abuse
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Acamprosate (this asset) | Massachusetts General Hospital | Approved | BB · 66 |
| Escitalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Naltrexone | VA Connecticut Healthcare System | P4 | BBB |
| Topiramate | University of California, San Francisco | P4 | BB |
| Quetiapine | University of Cincinnati | P4 | BB |
| Risperidone | Dartmouth-Hitchcock Medical Center | P4 | BB |
| 17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL | Sherwood Brown, MD, PhD | P4 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Centre hospitalier de l'Université de Montréal (CHUM) | P2 | BB |
| Ondansetron | University of Texas Southwestern Medical Center | P4 | BB |
+19 more in the Alcohol Abuse cohort
Other indications for Acamprosate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alcohol Dependence | — | P4 | BBB · 77 |
| Major Depressive Disorder | — | P4 | BB · 67 |
| Social Phobia | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Acamprosate in Alcohol Abuse. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/acamprosate-alcohol-abuse
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →